NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, Price Target & More

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its earnings results on Friday, May, 4th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.11) by $0.10. The business earned $144.40 million during the quarter, compared to analyst estimates of $144.01 million. Ionis Pharmaceuticals had a negative return on equity of 3.06% and a negative net margin of 2.00%. Ionis Pharmaceuticals's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period last year, the company earned $0.03 EPS. View Ionis Pharmaceuticals' Earnings History.

11 equities research analysts have issued 1-year price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $18.00 to $75.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $53.00 in the next twelve months. View Analyst Ratings for Ionis Pharmaceuticals.

Ionis Pharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 12,158,108 shares, an increase of 15.8% from the April 30th total of 10,497,036 shares. Based on an average daily volume of 1,696,916 shares, the days-to-cover ratio is presently 7.2 days. Currently, 9.8% of the company's shares are sold short. View Ionis Pharmaceuticals' Current Options Chain.

Some companies that are related to Ionis Pharmaceuticals include Mylan (MYL), BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), UCB (UCBJF), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Nektar Therapeutics (NKTR), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX) and SAGE Therapeutics (SAGE).

Press coverage about IONS stock has trended somewhat positive on Sunday, according to Accern. The research group scores the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Ionis Pharmaceuticals earned a coverage optimism score of 0.07 on Accern's scale. They also assigned media headlines about the company an impact score of 46.21 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Ionis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BB Biotech AG (6.79%), BlackRock Inc. (5.52%), Baillie Gifford & Co. (4.99%), OppenheimerFunds Inc. (2.29%), Pinnacle Associates Ltd. (0.99%) and American Century Companies Inc. (0.94%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

IONS stock was sold by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., JPMorgan Chase & Co., Van ECK Associates Corp, Pinnacle Associates Ltd., BlackRock Inc., Fiera Capital Corp, Altrinsic Global Advisors LLC and A.R.T. Advisors LLC. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

IONS stock was bought by a variety of institutional investors in the last quarter, including Summit Trail Advisors LLC, BB Biotech AG, Scout Investments Inc., Sector Gamma AS, Carillon Tower Advisers Inc., OppenheimerFunds Inc., UBS Group AG and Millennium Management LLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of IONS stock can currently be purchased for approximately $42.95.

Ionis Pharmaceuticals has a market capitalization of $5.29 billion and generates $507.67 million in revenue each year. The company earns $-5,960,000.00 in net income (profit) each year or $0.08 on an earnings per share basis. Ionis Pharmaceuticals employs 547 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.